Use of brom-ergocryptine in treating amenorrhea/galactorrhea.
Seven women with amenorrhea and galactorrhea, and no evidence of pituitary adenoma, were treated with brom-ergocryptine for two to 24 weeks. All seven patients had the resumption of regular menses within eight weeks, but six patients required 24 weeks of therapy to completely cease lacting. Two of the five women attempting to conceive became pregnant. Four of the five nonpregnant patients had a total recurrence of their symptoms after discontinuing the drug. Brom-ergocryptine appears to be very effective in inhibiting prolactin secretion and thus reestablishing normal ovulatory menstrual cycles and fertility.
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy*; D001971:Bromocriptine / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy*; D006801:Humans; D007775:Lactation Disorders / Q000188:drug therapy*; D011247:Pregnancy; D011388:Prolactin / Q000097:blood
D004873:Ergolines; D001971:Bromocriptine; D011388:Prolactin